Evidence map›Paper›PMID 40689050›Full record

ReviewJAAD international2025

FDA and EMA-approved noninvasive imaging techniques for basal cell carcinoma subtyping: A systematic review.

Mehdi Boostani, Giovanni Pellacani, Ximena Wortsman, Mariano Suppa, Mohamad Goldust, Carmen Cantisani, Paweł Pietkiewicz, Kende Lőrincz, András Bánvölgyi, Norbert M Wikonkál and 4 more

Abstract readReview
In one paragraph

Review in JAAD international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Dermoscopy-guided high-frequency ultrasound: Principles and applications in dermatology.JID innovations : skin science from molecules to population health · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mehdi BoostaniDepartment of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Giovanni PellacaniDepartment of Dermatology, Sapienza University of Rome, Rome, Italy.
Ximena WortsmanDepartment of Dermatology, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
Mariano SuppaGroupe d'Imagerie Cutanée Non-Invasive (GICNI) of the Société Française de Dermatologie (SFD), Paris, France.
Mohamad GoldustDepartment of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Carmen CantisaniDepartment of Dermatology, Sapienza University of Rome, Rome, Italy.
Paweł PietkiewiczCentrum Medyczne Zwierzyniecka, Poznań, Poland.
Kende LőrinczDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
András BánvölgyiDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
Norbert M WikonkálDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
Wendy J HussDepartment of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Kamran AvanakiRichard and Loan Hill Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, Illinois.
Gyorgy ParaghDepartment of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Norbert KissDepartment of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Basal cell carcinoma (BCC), the most common skin cancer, requires accurate subtyping for optimal treatment. While histopathology is the gold standard, noninvasive imaging offers a biopsy-free alternative, though its accuracy remains unclear. Objective: To assess the diagnostic accuracy of Food and Drug Administration- and European Medicines Agency-approved noninvasive imaging techniques for BCC subtyping. Methods: A systematic review included 19 studies (2650 lesions) from EMBASE, Scopus, PubMed, and Cochrane Library (published up to November 30, 2024). Evaluated modalities included dermoscopy, high-frequency ultrasound (HFUS), dermoscopy-guided HFUS (DG-HFUS), optical coherence tomography (OCT), high-definition OCT (HD-OCT), dynamic OCT (D-OCT), line-field confocal OCT (LC-OCT), and reflectance confocal microscopy. Results: Dermoscopy showed moderate accuracy (81.9% sensitivity, 81.8% specificity for superficial BCC [sBCC]). DG-HFUS outperformed HFUS (82.4% sensitivity, 91.3% specificity). LC-OCT had the highest accuracy, achieving 100% sensitivity for infiltrative BCC. D-OCT distinguished subtypes at 150 μm depth; branching vessels at 300 μm increased nBCC risk (relative risk = 1.53, Limitations: Study heterogeneity and inconsistent protocols limit comparability. Conclusion: LC-OCT and HD-OCT offer the highest accuracy, while DG-HFUS outperforms dermoscopy and HFUS, making them strong noninvasive alternatives.

Indexed as

basal cell carcinomadermoscopy-guided high-frequency ultrasounddynamic optical coherence tomography high-definition optical coherence tomographyhigh-frequency ultrasoundimagingline-field confocal optical coherence tomographynoninvasiveoptical coherence tomographyreflectance confocal microscopysubtypesubtyping

Identifiers

PMID40689050
PMCPMC12270798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.